tiprankstipranks
Trending News
More News >
Lifecore Biomedical (LFCR)
NASDAQ:LFCR

Lifecore Biomedical (LFCR) AI Stock Analysis

Compare
137 Followers

Top Page

LF

Lifecore Biomedical

(NASDAQ:LFCR)

Rating:51Neutral
Price Target:
$8.50
▲(3.79%Upside)
Lifecore Biomedical's overall score is impacted primarily by its challenging financial situation, characterized by high leverage and profitability issues. While technical indicators are positive, suggesting short-term momentum, valuation concerns due to negative profitability weigh heavily. The earnings call provides some optimism with strategic advancements, yet immediate financial challenges remain a risk.
Positive Factors
Business Development
The company continues to work on dozens of new business development opportunities, which include significant multinational pharmaceutical representation, a marked improvement from the company’s historical pipeline.
Financial Performance
Minimum volume commitments from Alcon represent a solid foundation for Lifecore’s achievable midterm revenue guide.
Negative Factors
Debt Levels
Lifecore has a highly leveraged balance sheet with approximately $180.1 million in debt and $44.3 million in convertible preferred stock.
Regulatory Risks
Lifecore could face quality-assurance problems with the FDA or another regulator.

Lifecore Biomedical (LFCR) vs. SPDR S&P 500 ETF (SPY)

Lifecore Biomedical Business Overview & Revenue Model

Company DescriptionLifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
How the Company Makes MoneyLifecore Biomedical makes money primarily through its contract development and manufacturing services, which involve producing injectable-grade hyaluronic acid and related biomaterials for its clients, including pharmaceutical and medical device companies. The company generates revenue by leveraging its expertise in fermentation and aseptic processing to manufacture products under strict regulatory compliance for its clients. Significant partnerships with these companies contribute to its earnings, as Lifecore's specialized capabilities and high-quality production processes are crucial for its clients' product development and commercialization needs.

Lifecore Biomedical Earnings Call Summary

Earnings Call Date:Apr 03, 2025
(Q3-2025)
|
% Change Since: 20.26%|
Next Earnings Date:Aug 27, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strategic advancements, new partnerships, and operational improvements, but was weighed down by decreased quarterly revenue and a significant net loss. The company remains optimistic about future growth and financial recovery.
Q3-2025 Updates
Positive Updates
New Customer Agreements and Partnerships
Lifecore signed multiple new agreements with both new and existing customers, including a significant agreement with Nirsum Laboratories and a post-quarter agreement with Humanetics.
Improved Financial Management
Cash flow from operations turned positive at $2 million, despite legacy legal expenses, and the company is on track to be cash flow positive in the second half of the fiscal year.
Strategic Focus and Future Growth Plans
Lifecore is focused on a 12% revenue CAGR and increasing EBITDA margins to over 25% over the next few years, with significant advancements in their late-stage pipeline towards commercialization.
Operational Efficiencies and Cost Reductions
Lifecore made substantial improvements in reducing operational expenses, improving productivity, and enhancing fermentation processing efficiency.
Negative Updates
Decrease in Quarterly Revenue
Revenues for the third quarter were $35.2 million, a decrease of 2% compared to the same period last year, primarily due to a decrease in CDMO revenues.
Net Loss for the Quarter
The company recorded a net loss of $14.8 million compared to net income of $15.6 million in the same period last year, affected by a prior year one-time favorable adjustment.
Increased SG&A Expenses
Selling, general, and administrative expenses for the quarter increased to $10.1 million from $9.8 million in the same period last year, driven by litigation and legacy legal matters.
Company Guidance
During Lifecore Biomedical's fiscal 2025 third quarter earnings call, the company reported revenues of $35.2 million, marking a 2% decrease from the prior year's $35.7 million. This decline was primarily attributed to a $1.5 million reduction in CDMO revenues, offset by a $1 million increase in hyaluronic acid manufacturing revenues. Gross profit for the quarter was $9.8 million, compared to $11.9 million in the previous year, with the net loss recorded at $14.8 million, contrasting sharply with a net income of $15.6 million from the same period last year. Selling, general, and administrative expenses totaled $10.1 million, slightly up from $9.8 million, driven by increased litigation expenses. Adjusted EBITDA was reported at $5.7 million, down from $6.4 million in the prior year. The company's guidance for fiscal 2025 remains unchanged, with expected revenues between $126.5 million and $130 million, and adjusted EBITDA forecasted between $19 million and $21 million.

Lifecore Biomedical Financial Statement Overview

Summary
Lifecore Biomedical faces significant financial challenges. Despite modest revenue growth, the company struggles with profitability, high leverage, and negative equity. Cash flow improvements are a positive aspect but insufficient to address broader financial weaknesses.
Income Statement
45
Neutral
Lifecore Biomedical's TTM revenue shows modest growth over the previous year, but profitability remains a concern. The company exhibits a negative EBIT and net profit margin, indicating operational challenges. Despite a slight revenue increase, the negative margins highlight potential inefficiencies or cost management issues.
Balance Sheet
30
Negative
The balance sheet reflects high leverage with a substantial debt-to-equity ratio, exacerbated by negative equity in the TTM period. The company's liabilities surpass assets, posing significant financial risks and limiting financial flexibility. The return on equity is not meaningful due to negative equity, which is a red flag for potential investors.
Cash Flow
50
Neutral
While Lifecore Biomedical's operating cash flow has improved in the TTM period, the free cash flow remains negative due to high capital expenditures. The operating cash flow to net income ratio is positive, indicating some operational cash generation despite net losses. However, the persistent negative free cash flow suggests ongoing capital strain.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue130.31M128.26M103.27M185.79M544.16M590.37M
Gross Profit43.59M41.85M27.29M50.55M81.47M74.99M
EBITDA-10.99M35.60M-35.98M1.96M13.00M-7.16M
Net Income-44.65M12.01M-102.19M-46.08M-32.66M-38.19M
Balance Sheet
Total Assets237.69M273.70M255.15M295.44M502.92M541.31M
Cash, Cash Equivalents and Short-Term Investments5.42M8.46M19.09M1.64M1.29M360.00K
Total Debt130.34M130.36M112.74M153.09M221.40M221.12M
Total Liabilities235.46M219.80M256.99M187.30M300.14M310.27M
Stockholders Equity2.23M53.90M-1.84M108.14M202.78M231.04M
Cash Flow
Free Cash Flow-10.74M-18.14M-55.22M-52.53M-8.75M-43.73M
Operating Cash Flow3.21M-217.00K-34.46M-24.40M15.02M-17.04M
Investing Cash Flow-6.96M-17.92M-4.15M81.77M-10.86M-23.89M
Financing Cash Flow6.09M7.51M39.70M-57.02M-3.42M40.02M

Lifecore Biomedical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price8.19
Price Trends
50DMA
6.86
Positive
100DMA
6.50
Positive
200DMA
6.33
Positive
Market Momentum
MACD
0.35
Negative
RSI
72.66
Negative
STOCH
83.96
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Positive. The current price of 8.19 is above the 20-day moving average (MA) of 7.13, above the 50-day MA of 6.86, and above the 200-day MA of 6.33, indicating a bullish trend. The MACD of 0.35 indicates Negative momentum. The RSI at 72.66 is Negative, neither overbought nor oversold. The STOCH value of 83.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFCR.

Lifecore Biomedical Risk Analysis

Lifecore Biomedical disclosed 37 risk factors in its most recent earnings report. Lifecore Biomedical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Lifecore Biomedical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
EBEBS
54
Neutral
$344.66M-21.63%-18.56%76.88%
54
Neutral
$166.33M-48.14%-29.69%-105.88%
53
Neutral
$322.82M77.48%5.29%-37.31%
51
Neutral
$7.41B0.36-61.88%2.33%16.99%1.69%
51
Neutral
$303.24M-83.58%6.88%-17.54%
50
Neutral
$196.93M23.44%12.99%17.78%
45
Neutral
$273.08M-28.76%3.79%55.19%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LFCR
Lifecore Biomedical
8.19
3.47
73.52%
EBS
Emergent Biosolutions
6.35
-0.71
-10.06%
ESPR
Esperion
0.99
-1.35
-57.69%
AQST
Aquestive Therapeutics
3.25
0.80
32.65%
TKNO
Alpha Teknova
5.11
3.90
322.31%
DERM
Journey Medical Corp
7.14
1.77
32.96%

Lifecore Biomedical Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Lifecore Biomedical Strengthens Financial Position with Key Moves
Positive
Nov 26, 2024

Lifecore Biomedical, Inc. has strategically amended its asset-based lending revolving credit facility with BMO, extending the term by three years to 2027 and reducing interest rates. This move, alongside a recent $24.3 million private placement, significantly strengthens Lifecore’s financial position and supports its growth strategy in the expanding CDMO market. The company is enhancing its capabilities with new management, advanced manufacturing equipment, and new customer agreements.

Business Operations and Strategy
Lifecore Biomedical Plans Strategic Growth and Transformation
Positive
Nov 21, 2024

Lifecore Biomedical, Inc., a leader in complex injectables, is poised for sustainable growth with a strategic plan to achieve over 12% revenue CAGR and 25%+ EBITDA margins. The company is leveraging its robust capabilities and experienced management team to capitalize on market opportunities, aiming to support $300 million in annual revenue. Lifecore’s transformation into a standalone CDMO with enhanced technical and regulatory strengths positions it as a compelling player in the financial markets.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 25, 2025